Flurpiridaz F-18 is a radiopharmaceutical drug used for positron emission tomography (PET) myocardial perfusion imaging (MPI). Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.
- Mechanism
- Curator reviewed · 4 references
MPI is a common imaging process for detecting CAD: It identifies stress-induced perfusion defects caused by hemodynamically significant coronary stenoses.
Flurpiridaz F-18 binds to mitochondrial complex 1. Flurpiridaz F-18 is extracted by the myocardium proportional to the blood flow and binds to heart tissue that has biologically active mitochondria. Therefore, radioactivity in viable myocardium is higher than in infarcted tissue.
- Primary indication
- Flurpiridaz F-18 is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial...Curator reviewed · 1 structured indication
- Formula / weight
- C18H22ClFN2O3 · 367.84 g/mol (avg)
- First approval
- United States, 2025
- Code names
- BMS-747158 · BMS 747158-02
Resolves to
RMXZKEPDYBTFOS-LRFGSCOBSA-NSMILESCC(C)(C)N1N=CC(OCC2=CC=C(COCC[18F])C=C2)=C(Cl)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Flurpiridaz F-18, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account